FDA Approves DEPAKOTE — AbbVie Inc.

# FDA Approval Newswire AbbVie Inc.'s DEPAKOTE (divalproex sodium) received FDA approval on March 10, 1983, establishing a foundational anticonvulsant therapy that would capture significant market share in the epilepsy and psychiatric disorder treatment segments for decades. The oral formulation's approval positioned AbbVie as a key player in the growing neurology pharmaceutical market, generating billions in cumulative revenues through its broad therapeutic applications in seizure disorders, bipolar disorder, and migraine prevention.